Akari Therapeutics (AKTX) Short-Term Debt issuances (2025 - 2026)
Akari Therapeutics recorded quarterly Short-Term Debt issuances of -$33000.0 in Q1 2026, little changed quarter-over-quarter from -$33000.0 in Q3 2025, and up 91.87% year-over-year from -$17199.0 in Q1 2025.
Akari Therapeutics' Short-Term Debt issuances history runs 2 years deep, the most recent figure standing at -$33000.0 for Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -33,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,000.00 |
| Mar 31, 2026 | -33,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Sep 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -406,000.00 |
| Mar 31, 2025 | -406,000.00 |